Option Care Health (NASDAQ:OPCH) Posts Quarterly Earnings Results, Meets Expectations

Option Care Health (NASDAQ:OPCH) issued its earnings results on Wednesday. The company reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49, FiscalAI reports. The business had revenue of $1.49 billion for the quarter, compared to analyst estimates of $1.48 billion. Option Care Health had a net margin of 3.68% and a return on equity of 18.74%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.45 EPS.

Option Care Health Price Performance

Shares of OPCH traded down $0.07 on Wednesday, hitting $31.70. The company’s stock had a trading volume of 2,025,721 shares, compared to its average volume of 2,976,403. The company has a market capitalization of $4.75 billion, a PE ratio of 23.84, a PEG ratio of 1.93 and a beta of 0.47. Option Care Health has a fifty-two week low of $18.01 and a fifty-two week high of $36.80. The company has a 50 day moving average price of $26.83 and a 200 day moving average price of $26.44. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.47 and a quick ratio of 0.98.

Key Option Care Health News

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Q3 revenue rose 4.1% year over year to $1.49 billion, topping estimates of about $1.48 billion. Adjusted earnings were $0.49 per share, matching the $0.49 consensus cited by several reports and beating Zacks’ $0.48 estimate; EPS was up from $0.45 a year earlier. Option Care Health Q3 results Zacks Q3 earnings report
• Neutral Sentiment: Two law firms announced investigations related to the fairness of a merger involving OPCH. The notices provide no specific findings or details in the supplied reports, so the implications for shareholders—and any potential effect on the stock—are unclear. Merger investigation notice

Analyst Ratings Changes

A number of research firms have weighed in on OPCH. JPMorgan Chase & Co. downgraded Option Care Health from an “overweight” rating to a “neutral” rating and set a $33.00 price objective on the stock. in a report on Wednesday, October 7th. Jefferies Financial Group downgraded Option Care Health from a “buy” rating to a “hold” rating and raised their target price for the stock from $28.00 to $32.05 in a research report on Tuesday, October 6th. Wall Street Zen upgraded Option Care Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Stephens cut Option Care Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $30.00 to $24.00 in a report on Friday, July 17th. Finally, UBS Group downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and reduced their target price for the company from $39.00 to $32.05 in a research note on Friday, October 9th. Two analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, Option Care Health has a consensus rating of “Hold” and a consensus price target of $29.48.

Option Care Health Company Profile

Option Care Health, Inc is an independent provider of home and alternate-site infusion services in the United States. The company coordinates and delivers infusion therapy outside traditional hospital settings, including patients’ homes, ambulatory infusion suites and other outpatient locations.

Its services include administration of anti-infective therapies, immune globulin, nutrition support, inotropic therapies and medications used in the treatment of chronic and complex conditions.